VivoSeq
Other

Regression

0

Pipeline Programs↗

1

Active Trials↗

3

Companies Involved↗

Regression is an early-stage landscape with 0 programs across 3 companies. The most active players are Cerenis Therapeutics, SA, GSK, Daiichi Sankyo.

Intelligence

Pipeline Metrics

Competitive Density

6/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

80/100

Attrition Rate

17/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

C

Cerenis Therapeutics, SA

0 programs

PreclinicalGSK logo

GSK

0 programs

PreclinicalDaiichi Sankyo logo

Daiichi Sankyo

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

12

clinical trials

Completed8 · 67%
Withdrawn1 · 8%
Terminated1 · 8%
Unknown status1 · 8%
Recruiting1 · 8%

Clinical Trials

Trial Activity

12 trials

Natural History of Glycosphingolipid Storage Disorders and Glycoprotein Disorders
Recruiting·NNational Human Genome Research Institute (NHGRI)·N/A·NCT00029965·200 enrolled
Regression of Myocardial Steatosis by Nebivolol
Completed·—·Phase 1·NCT01358409·31 enrolled
Plaque Regression and Progenitor Cell Mobilization With Intensive Lipid Elimination Regimen (PREMIER), Phase II
Completed·VVA Office of Research and Development·Phase 3·NCT02347098·270 enrolled
Exploratory Study of Plaque Regression
Completed·CCerenis Therapeutics, SA·Phase 2·NCT01515241·10 enrolled
The CLEVER Study - Coreg And Left Ventricular Mass Regression
Completed·GSK logoGSK·Phase 3·NCT00108082·287 enrolled
Intima Media Thickness Regression in Dyslipidemic Teenagers
Completed·UUniversité de Montréal·Phase 3·NCT01768481·16 enrolled
Plaque Regression and Progenitor Cell Mobilization With Intensive Lipid Elimination Regimen (PREMIER), Phase I
Completed·VVA Office of Research and Development·Phase 3·NCT01004406·59 enrolled
Hypertrophic Regression With N-Acetylcysteine in HCM
Completed·TThe University of Texas Health Science Center, Houston·Phase 1·NCT01537926·42 enrolled
Bilateral, Masked Comparison of PEG-400 Based Artificial Tear vs. Systane for Dry Eye Signs, Symptoms & Refractive Regression Associated With Myopic Laser in Situ Keratomilieusis (LASIK).
Completed·BBp Consulting, Inc·Phase 4·NCT00620893·100 enrolled
The Confirmatory Olmesartan Plaque Regression Study
Terminated·Daiichi Sankyo logoDaiichi Sankyo·Phase 4·NCT01132768·114 enrolled
Regression of Fatty Heart by Valsartan Therapy
Withdrawn·UUniversity of Texas Southwestern Medical Center·Phase 4·NCT00745953
Interval of Disease Inactivity After Complete Polypoidal Regression in PCV Receiving Aflibercept
Unknown status·—·N/A·NCT04707027·80 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)